1 – 102 of 102
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
805P Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
(
- Contribution to journal › Published meeting abstract
- 2022
-
Mark
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
(
- Contribution to journal › Published meeting abstract
- 2021
-
Mark
Newly diagnosed and relapsed follicular lymphoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2021) In Annals of oncology : official journal of the European Society for Medical Oncology 32(3). p.298-308(
- Contribution to journal › Article
- 2019
-
Mark
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities : further results from the prospective PANTHER study with focus on obese patients
2019) In Annals of oncology : official journal of the European Society for Medical Oncology 30(1). p.109-114(
- Contribution to journal › Article
-
Mark
Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment
2019) In Annals of oncology : official journal of the European Society for Medical Oncology 30(4). p.604-611(
- Contribution to journal › Article
-
Mark
High expression of estrogen receptor beta correlates with anti-tumorigenic and anti-proliferative inflammatory proteins in colorectal cancer patients
(
- Contribution to journal › Article
-
Mark
To investigate the role of PGD2 and its receptor signalling in colon cancer pathophysiology
(
- Contribution to journal › Article
-
Mark
15-PGDH regulated PD-1/PD-L1 immune checkpoint blockade immunotherapy in colon cancer is a TNF-α dependent phenomenon
(
- Contribution to journal › Article
- 2018
-
Mark
Characterization of male breast cancer : Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
(
- Contribution to journal › Article
-
Mark
Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers
2018) In Annals of Oncology(
- Contribution to journal › Article
-
Mark
Man against machine : diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists
2018) In Annals of oncology : official journal of the European Society for Medical Oncology 29(8). p.1836-1842(
- Contribution to journal › Article
-
Mark
Stromal progesterone receptor expression and long-term survival in patients with resected periampullary adenocarcinoma
2018) In Annals of oncology : official journal of the European Society for Medical Oncology 29(Suppl. 8). p.262-263(
- Contribution to journal › Published meeting abstract
-
Mark
Pre-diagnostic anthropometry, sex, and risk of colorectal cancer according to tumor-infiltrating immune cell composition
2018) In Annals of oncology : official journal of the European Society for Medical Oncology 29(Suppl. 8). p.180-180(
- Contribution to journal › Published meeting abstract
-
Mark
Discovery of KIRREL as a biomarker for prognostic stratification of patients with thin melanoma
2018) In Annals of oncology : official journal of the European Society for Medical Oncology 29(Suppl. 8). p.463-463(
- Contribution to journal › Published meeting abstract
-
Mark
Prognostic significance of lymphocyte-activation gene-3 expression in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma
2018) In Annals of oncology : official journal of the European Society for Medical Oncology 29(Suppl. 8). p.220-220(
- Contribution to journal › Published meeting abstract
-
Mark
Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
2018) In Annals of oncology : official journal of the European Society for Medical Oncology 29(Suppl. 8). p.65-65(
- Contribution to journal › Published meeting abstract
-
Mark
A phase III study of INCB054828 as adjuvant therapy in patients (pts) with high-risk urothelial carcinoma (UC) harboring fibroblast growth factor receptor 3 (FGFR3) genomic alterations
2018) In Annals of oncology : official journal of the European Society for Medical Oncology 29(Suppl. 8). p.328-328(
- Contribution to journal › Article
-
Mark
Intermediate prognosis in metastatic germ cell tumors (IPGCT) : Outcome and prognostic stratification
2018) In Annals of oncology : official journal of the European Society for Medical Oncology 29. p.325-325(
- Contribution to journal › Article
- 2016
-
Mark
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic
(
- Contribution to journal › Article
-
Mark
Cancer mortality in cohorts of workers in the European rubber manufacturing industry first employed since 1975.
(
- Contribution to journal › Article
-
Mark
A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial
(
- Contribution to journal › Article
- 2015
-
Mark
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
(
- Contribution to journal › Article
-
Mark
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
(
- Contribution to journal › Article
-
Mark
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
(
- Contribution to journal › Article
- 2014
-
Mark
Cancer risk in amyloidosis patients in Sweden with novel findings on non-Hodgkin lymphoma and skin cancer
(
- Contribution to journal › Article
-
Mark
Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype
(
- Contribution to journal › Article
-
Mark
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
(
- Contribution to journal › Article
-
Mark
Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper (Annals Oncology Jan;25(1): 9-15, 2014).
(
- Contribution to journal › Letter
-
Mark
Autoimmune diseases associated with non-Hodgkin lymphoma: A nationwide cohort study.
(
- Contribution to journal › Article
-
Mark
One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group.
(
- Contribution to journal › Article
-
Mark
37p * androgen receptor expression in a population-based prospective breast cancer cohort.
(
- Contribution to journal › Published meeting abstract
-
Mark
32p * biomarkers and molecular subtypes in primary breast tumors and metastases: associations with liver metastases and outcome.
(
- Contribution to journal › Article
-
Mark
71p * statin-induced anti-proliferative effects via cyclin d1 and p27 in a window-of-opportunity breast cancer trial.
(
- Contribution to journal › Published meeting abstract
-
Mark
Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
2014) In Annals of oncology : official journal of the European Society for Medical Oncology 25(4). p.864-869(
- Contribution to journal › Article
- 2013
-
Mark
Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort
(
- Contribution to journal › Article
-
Mark
Consumption of fish and meats and risk of hepatocellular carcinoma: the European Prospective Investigation into Cancer and Nutrition (EPIC)
(
- Contribution to journal › Article
-
Mark
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
(
- Contribution to journal › Article
-
Mark
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
(
- Contribution to journal › Article
-
Mark
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
(
- Contribution to journal › Scientific review
-
Mark
Dietary intake of acrylamide and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort
(
- Contribution to journal › Article
-
Mark
A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial.
(
- Contribution to journal › Article
-
Mark
The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.
(
- Contribution to journal › Article
-
Mark
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
(
- Contribution to journal › Article
-
Mark
Regarding the letter to the editor 'AIB1 and its significant role in tumor pathogenesis in systemic malignancies: beyond breast carcinomas' by Kapoor and Shailendra in Annals of Oncology.
(
- Contribution to journal › Letter
-
Mark
Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.
(
- Contribution to journal › Article
- 2012
-
Mark
Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer
(
- Contribution to journal › Article
-
Mark
Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries?
(
- Contribution to journal › Article
-
Mark
Power and limits of modern cancer diagnostics: cancer of unknown primary
(
- Contribution to journal › Article
-
Mark
Autoimmune disease and subsequent digestive tract cancer by histology
(
- Contribution to journal › Article
-
Mark
CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group
(
- Contribution to journal › Article
-
Mark
Adjuvant therapy in primary GIST: state-of-the-art
(
- Contribution to journal › Scientific review
-
Mark
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation
(
- Contribution to journal › Article
-
Mark
Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project
(
- Contribution to journal › Article
-
Mark
Survival in cancer of unknown primary site: population-based analysis by site and histology
(
- Contribution to journal › Article
-
Mark
Effect of autoimmune diseases on mortality and survival in subsequent digestive tract cancers
(
- Contribution to journal › Article
-
Mark
Acupuncture compared with placebo acupuncture in radiotherapy-induced nausea-a randomized controlled study
(
- Contribution to journal › Article
-
Mark
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
(
- Contribution to journal › Article
-
Mark
Death causes in breast cancer patients
(
- Contribution to journal › Article
-
Mark
Subsequent cancers in patients diagnosed with cancer of unknown primary (CUP): etiological insights?
(
- Contribution to journal › Article
- 2011
-
Mark
Survival in cancer patients with previous hospitalization for sarcoidosis: a Swedish population-based cohort study during 1964-2006.
(
- Contribution to journal › Article
-
Mark
Metabolic syndrome and rare gynecological cancers in the Metabolic syndrome and Cancer project (Me-Can)
(
- Contribution to journal › Article
-
Mark
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol
(
- Contribution to journal › Article
- 2010
-
Mark
Second cancers after testicular cancer diagnosed after 1980 in Sweden
(
- Contribution to journal › Article
-
Mark
Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study
(
- Contribution to journal › Article
-
Mark
STROMA-DERIVED MARKERS PREDICTING BREAST CANCER PROGNOSIS AND TREATMENT RESPONSE
(
- Contribution to journal › Published meeting abstract
-
Mark
AIB1 is a predictive factor for tamoxifen response in premenopausal women.
(
- Contribution to journal › Article
-
Mark
Vandetanib In Locally Advanced Or Metastatic Differentiated Thyroid Cancer (Papillary Or Follicular; Dtc): A Randomized, Double-Blind Phase Ii Trial
2010) 35th European-Society-for-Medical-Oncology (ESMO) Congress In Annals of Oncology 21. p.315-315(
- Contribution to journal › Published meeting abstract
-
Mark
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
(
- Contribution to journal › Article
-
Mark
Characterisation Of The Hepatic Safety Profile Of Trabectedin: Pooled Analysis Of 19 Phase II Clinical Trials (CTS) In 1132 Patients With Solid Tumours
2010) 35th European-Society-for-Medical-Oncology (ESMO) Congress In Annals of Oncology 21(Suppl. 8). p.177-178(
- Contribution to journal › Published meeting abstract
-
Mark
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
(
- Contribution to journal › Article
-
Mark
Histology-driven chemotherapy of soft-tissue sarcoma.
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2009
-
Mark
DEVELOPMENT OF IMMUNOHISTOCHEMICAL SURROGATES FOR PREDICTION OF BREAST CANCER PATIENT OUTCOME VIA HIGH-THROUGHPUT ANTIBODY GENERATION AND APPLICATION OF TISSUE MICROARRAY TECHNOLOGY: AN INITIAL REPORT
(
- Contribution to journal › Published meeting abstract
-
Mark
Empirically derived psychosocial states among adolescents diagnosed with cancer during the acute and extended phase of survival
(
- Contribution to journal › Article
-
Mark
Cancer risk in hospitalized sarcoidosis patients: a follow-up study in Sweden
(
- Contribution to journal › Article
-
Mark
IDENTIFICATION OF NOVEL SECRETED TUMOR STROMA-DERIVED STIMULATORS OF PROSTATE CANCER GROWTH
2009) 7th International Symposium on Targeted Anticancer Therapies In Annals of Oncology 20(Suppl 3). p.34-34(
- Contribution to journal › Published meeting abstract
-
Mark
Cancer risks in Crohn disease patients
2009) In Annals of oncology : official journal of the European Society for Medical Oncology 20(3). p.80-574(
- Contribution to journal › Article
- 2008
-
Mark
Mature T-cell lymphoma patients show high relapse rates after high dose therapy followed by autologous transplantation
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.113-114(
- Contribution to journal › Published meeting abstract
-
Mark
Burkitt's lymphoma: Comparison of 2 nationwide population-based lymphoma registries
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.131-131(
- Contribution to journal › Published meeting abstract
-
Mark
Nordic Observational Study Evaluating Safety And Analgesic Use In Patients With Advanced Cancer Under Zoledronic Acid Treatment Interim Analysis
(
- Contribution to journal › Published meeting abstract
-
Mark
Sox11, a non-B cell lineage transcription factor, is overexpressed in mantle cell lymphoma
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.172-173(
- Contribution to journal › Published meeting abstract
-
Mark
Self-selection in sigmoidoscopy screening: A nine-year follow-up study
(
- Contribution to journal › Published meeting abstract
-
Mark
a multicentre, phase ii study of cp-4055 in combination with sorafenib in patients with metastatic malignant melanoma
(
- Contribution to journal › Published meeting abstract
-
Mark
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
(
- Contribution to journal › Article
-
Mark
Familial characteristics of Waldenström's macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL): A population-based study in Sweden
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.166-166(
- Contribution to journal › Published meeting abstract
-
Mark
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
(
- Contribution to journal › Article
-
Mark
Transformed diffuse large B cell lymphomas differ from follicular lymphomas in both gene and protein expression
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.111-111(
- Contribution to journal › Published meeting abstract
-
Mark
Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST)
(
- Contribution to journal › Article
-
Mark
BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.142-142(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
(
- Contribution to journal › Article
-
Mark
Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up
(
- Contribution to journal › Article
-
Mark
Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers
(
- Contribution to journal › Article
-
Mark
Targeted therapy in nuclear medicine current status and future prospects
(
- Contribution to journal › Article
- 2006
-
Mark
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe
(
- Contribution to journal › Article
- 2004
-
Mark
External quality assessment for mutation detection in the BRCA1 and BRCA2 genes: EMQN's experience of 3 years
(
- Contribution to journal › Article
-
Mark
Colon cancer prevalence and estimation of differing care needs of colon cancer patients
(
- Contribution to journal › Article
-
Mark
Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma
(
- Contribution to journal › Article
- 2003
-
Mark
Cancer prevalence in Northern Europe: the EUROPREVAL study.
(
- Contribution to journal › Article
- 2002
-
Mark
Measuring cancer prevalence in Europe: the EUROPREVAL project
(
- Contribution to journal › Article
-
Mark
Cancer prevalence in European registry areas
(
- Contribution to journal › Article
- 2001
-
Mark
Neuroendocrine pathogenesis in adenocarcinoma of the prostate
(
- Contribution to journal › Article
-
Mark
Computed tomography of pulmonary metastases from osteosarcoma: The less poor technique. A study of 51 patients with histological correlation
(
- Contribution to journal › Article
- 1999
-
Mark
CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial
(
- Contribution to journal › Article